Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors

被引：0
|
作者：
Qin, Shukui
Cheng, Ying
Wang, Qiming
Cheng, Shuxia
Chai, Xiaoli
Wu, Lihua
Yu, Yan
Shi, Jianhua
Li, Xiumin
Fan, Lianlian
Xia, Jin
Huang, Yisheng
Ji, Yinghua
Zhuang, Zhixiang
Yang, Lei
Jiang, Ou
Zheng, Qinhong
Liao, Sihai
Yi, Shanyong
Ye, Huangyang
机构：
[1] Nanjing Chinese Med Univ, Jinling Hosp, Canc Ctr, Nanjing, Peoples R China
[2] Jilin Canc Hosp, Changchun, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Peoples R China
[5] ChangSha TaiHe Hosp, Changsha, Peoples R China
[6] Shulan (Hangzhou) Hosp, Hangzhou, Peoples R China
[7] Harbin Med Univ, Internal Med Dept 6, Canc Hosp, Harbin, Peoples R China
[8] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[9] Linyi Canc Hosp, Dept Gynecol Oncol, Linyi, Shandong, Peoples R China
[10] Deyang Peoples Hosp, Deyang, Peoples R China
[11] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[12] Maoming Peoples Hosp, Dept Oncol, Maoming, Peoples R China
[13] Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China
[14] Soochow Univ, Dept Oncol, Affiliated Hosp 2, Suzhou, Peoples R China
[15] Nantong Canc Hosp, Nantong, Peoples R China
[16] Second Peoples Hosp Neijiang, Neijiang, Peoples R China
[17] Peoples Hosp Quzhou, Quzhou, Peoples R China
[18] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China
[19] Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[20] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2611
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
    Liu, Rujiao
    Li, Wenhua
    Meng, Yanchun
    Gao, Shuiping
    Zhang, Jian
    Hu, Xichun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [42] Phase I study of anti-PD-L1 antibody MPDL3280A in patients with advanced solid tumors
    Murakami, Haruyasu
    Yamamoto, Noboru
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    Fujiwara, Yutaka
    Mizugaki, Hidenori
    Ishida, Yoshimasa
    Kawakami, Tomohisa
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [43] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors
    Prenen, H.
    Kyi, C.
    Van Lancker, G.
    Patel, S. P.
    Mittag, D.
    Weaver, A.
    Bol, K.
    Stalbovskaya, V.
    Pulini, J.
    Zhou, G.
    Dong, Z.
    Asatiani, E.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1436 - S1436
  • [45] First-in-human study of ZGGS15, a dual specific antibody targeting LAG-3 and TIGIT, as monotherapy in patients with advanced solid tumors
    Zhu, Ji
    Wang, Zhen
    Chai, Xiaoli
    Wu, Lihua
    Qu, Song
    Liu, Linlin
    Liu, Yanyan
    Sun, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors
    Zhang, J.
    Liu, R.
    Gao, S.
    Li, X.
    Chen, J.
    Yao, X.
    Fang, Y.
    Li, R.
    Zhang, M.
    Qiu, F.
    Li, Y.
    Liu, T.
    Huang, H.
    Zhang, X.
    Guo, H.
    Hu, B.
    Liu, J-Y.
    Yang, Q.
    Zhao, P.
    Wang, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S464 - S464
  • [47] Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial
    Du, Yiqun
    Zhang, Jian
    Sun, Meili
    Wen, Qing
    Zheng, Yawen
    Tolcher, Anthony W.
    Sommerhalder, David
    Wang, Zhen
    Li, Xiumin
    Gao, Zhenyuan
    Zhou, Huan
    Liu, Lian
    Wang, Benjie
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Li, Chao
    Li, Jiangfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors
    Hashimoto, Kenji
    Perera, Ayesh
    Ogita, Yoshitaka
    Nakamura, Mikiko
    Ishiguro, Takahiro
    Sano, Yuji
    Kinoshita, Yasuko
    Sakurai, Mika Kamata
    Frings, Werner
    Komatsu, Shun-ichiro
    Kaneko, Akihisa
    Ueda, Masamichi
    Kishishita, Shohei
    Gianella-Borradori, Athos
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors
    Fiedler, Walter M.
    Wolf, Martin
    Kebenko, Maxim
    Goebeler, Marie-Elisabeth
    Ritter, Barbara
    Quaas, Alexander
    Vieser, Eva
    Hijazi, Youssef
    Patzak, Ingrid
    Friedrich, Matthias
    Kufer, Peter
    Frankel, Stanley
    Seggewiss-Bernhardt, Ruth
    Kaubitzsch, Sabine
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Preliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies
    Seitz, L. C.
    Rieger, A.
    Berry, W.
    Ashok, D.
    Direnzo, D.
    Jin, L.
    Lee, S. J.
    Park, A.
    Piovesan, D.
    Tan, J. B. L.
    Walters, M. J.
    Karakunnel, J.
    ANNALS OF ONCOLOGY, 2018, 29
12345